Dalla rassegna internazionale e quotidiana delle ultime notizie dal mondo digitale, segnaliamo oggi…
Bilibili launches $621 million offering, as China techs tap markets after IPOs
Chinese video platform Bilibili launched on Tuesday a convertible bond sale and a follow-on share offering that could raise around $621 million combined, in a return to the capital markets just over a year after it went public in New York. Bilibili, one of China’s leading online video sharing and entertainment platforms, announced the fundraising on Tuesday but did not disclose detailed terms. The company is selling a $300 million seven-year convertible bond and 17.1 million shares, of which 10.55 million are primary and the rest come from an existing shareholder, according to a term sheet seen by Reuters. (Fonte: Reuters)
German fintech company builder Finleap acquires SME banking provider Penta
Just since months after raising $7 million in Series A funding, German SME banking provider Penta has been acquired by Finleap. Terms of the deal remain undisclosed. Launched in late 2014 by Hitfox Group and Ramin Niroumand, Finleap has developed 16 ventures from scratch, as well as acquiring a number of fintechs. Companies in its portfolio include banking platform solarisBank, of which Penta is a customer, and digital insurer Element, to name just two. Penta says that becoming part of the Finleap “ecosystem” will help the SME banking provider increase the speed at which it expands internationally. This will include launching in Italy in partnership with Beesy, a Finleap portfolio company focusing on digital business banking for freelancers.
Creato il primo Dna di un organismo vivente da un algoritmo
A 11 anni dal primo genoma artificiale, prodotto in provetta dal pioniere delle ricerche sulla vita sintetica Craig Venter, arriva il primo Dna di un organismo vivente interamente generato da un algoritmo: ha la forma di una molecola circolare con 680 geni artificiali, “riscritti” semplificando quelli di un batterio d’acqua dolce (Caulobacter crescentus). Presto potrebbe essere trasferito in una cellula per dare vita al nuovo batterio sintetico Caulobacter ethensis-2.0. Lìobiettivo è infatti quello di usare i batteri sintetici come “fabbriche” di farmaci e vaccini. A indicarlo è lo studio pubblicato sulla rivista dell’Accademia americana delle scienze (Pnas) dai ricercatori del Politecnico di Zurigo (Eth), che spiegano come sono riusciti ad abbattere tempi e costi rispetto a quelli affrontati da Venter. (Fonte: Il Sole 24 Ore)
© RIPRODUZIONE RISERVATA
